Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of benmelstobart in combination with anlotinib and chemotherapy sequential benmelstobart in combination with anlotinib for the first-line treatment of extensive-stage small cell lung cancer.
Extensive-stage Small Cell Lung Cancer
DRUG: Benmelstobart|DRUG: Anlotinib|DRUG: Carboplatin or cisplatin|DRUG: Etoposide
Progression Free Survival (PFS), The time from treatment to the first documented progressive disease (PD) assessed by the investigator according to RECIST 1.1 or death for any reason. Evaluated every 2 cycles/6 weeks on treatment and every 3 months in follow-up., Approximately 7 months from treatment.
Overall Survival (OS), The time from treatment to death due to any cause. Follow-up visits were made every 3 months after the end of treatment., Approximately 14 months from treatment.|Objective Response Rate (ORR), Percentage of participants who achieved Complete Response (CR) or Partial Response (PR), assessed by the investigator according to RECIST 1.1., Approximately 12 weeks after the last participant begin study treatment.|Duration of Response (DOR), The time from the first response (Complete Response (CR) or Partial Response (PR)) to disease progression (PD) assessed by the investigator according to RECIST 1.1 or death for any reason., Approximately 7 months from treatment.|Disease Control Rate (DCR), Percentage of participants who achieved Complete Response (CR), Partial Response (PR) or Stable Disease (SD), assessed by the investigator according to RECIST 1.1., Approximately 12 weeks after the last participant begin study treatment.|Safety (Adverse Events (AEs)), Type and severity of adverse events according to CTCAE v5.0; calculation of the incidence of adverse events and their incidence by system., From enrollment until 30 days after the end of treatment.
The goal of this clinical trial is to evaluate the efficacy and safety of benmelstobart in combination with anlotinib and chemotherapy sequential benmelstobart in combination with anlotinib for the first-line treatment of extensive-stage small cell lung cancer.